Authors: ETTE EI HOWIE CA KELMAN AW WHITING B

Citation: Ei. Ette et al., EXPERIMENTAL-DESIGN AND EFFICIENT PARAMETER-ESTIMATION IN PRECLINICALPHARMACOKINETIC STUDIES, Pharmaceutical research, 12(5), 1995, pp. 729-737

Authors: ETTE EI KELMAN AW HOWIE CA WHITING B

Citation: Ei. Ette et al., ANALYSIS OF ANIMAL PHARMACOKINETIC DATA - PERFORMANCE OF THE ONE-POINT PER ANIMAL DESIGN, Journal of pharmacokinetics and biopharmaceutics, 23(6), 1995, pp. 551-566

Authors: ANDERSON JE MUNDAY AS KELMAN AW WHITING B BRIGGS JD KNEPIL J THOMSON AH

Citation: Je. Anderson et al., EVALUATION OF A BAYESIAN-APPROACH TO THE PHARMACOKINETIC INTERPRETATION OF CYCLOSPORINE CONCENTRATIONS IN RENAL-ALLOGRAFT RECIPIENTS, Therapeutic drug monitoring, 16(2), 1994, pp. 160-165

Authors: ETTE EI KELMAN AW HOWIE CA WHITING B

Citation: Ei. Ette et al., INTERPRETATION OF SIMULATION STUDIES FOR EFFICIENT ESTIMATION OF POPULATION PHARMACOKINETIC PARAMETERS, The Annals of pharmacotherapy, 27(9), 1993, pp. 1034-1039

Authors: WADE JR KELMAN AW HOWIE CA WHITING B

Citation: Jr. Wade et al., EFFECT OF MISSPECIFICATION OF THE ABSORPTION PROCESS ON SUBSEQUENT PARAMETER-ESTIMATION IN POPULATION ANALYSIS, Journal of pharmacokinetics and biopharmaceutics, 21(2), 1993, pp. 209-222

Authors: MILLIGAN PA MCGILL PE HOWDEN CW KELMAN AW WHITING B

Citation: Pa. Milligan et al., THE CONSEQUENCES OF H-2-RECEPTOR ANTAGONIST PIROXICAM COADMINISTRATION IN PATIENTS WITH JOINT DISORDERS, European Journal of Clinical Pharmacology, 45(6), 1993, pp. 507-512